NEUP Neuphoria Therapeutics Inc.

$3.87

Neuphoria Therapeutics Inc. (NEUP) is expected to report earnings on August 28, 2026, before the market open. The consensus earnings estimate is a loss of $0.56 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -24.1% since its last earnings release on May 15, 2026.

Neuphoria Therapeutics Beat Consensus Estimates
Friday, May 15, 2026 · 12:00 AM ET
Earnings Date
4th Quarter, Jun 2026
Aug 28
Friday · Before Open
Earnings Whisper
-
vs ($0.56)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $4.00

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Neuphoria Therapeutics Inc.

Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.

Sector

Healthcare

Industry

Biotechnology